Paul M. Harari
保罗·哈拉里
MD
Chairman and Doris Albright Mower Professor, Department of Human Oncology人类肿瘤学系主任兼多丽丝·阿尔布莱特·莫尔教授
👥Biography 个人简介
Paul Harari is a national leader in head and neck cancer radiation oncology at University of Wisconsin. He pioneered molecularly targeted radiosensitization strategies, particularly EGFR inhibition combined with radiotherapy, shaping standard-of-care protocols for locally advanced HNSCC.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Cetuximab + Radiotherapy Standard of Care
Pioneered clinical use of cetuximab combined with radiotherapy for locally advanced head and neck cancer, establishing a new treatment standard.
EGFR Radiosensitization Strategy
Led translational studies defining EGFR pathway modulation as a radiosensitization strategy in squamous cell carcinomas.
NRG/RTOG Cooperative Group Trials
Directed multi-institutional cooperative group trials improving locoregional control rates in head and neck malignancies.
Representative Works 代表性著作
Molecular target modulation, imaging, and dosimetry studies in cetuximab-treated head and neck cancer patients
Clinical Cancer Research (2010)
Linked cetuximab tumor uptake to EGFR inhibition and radiosensitization in vivo.
Bioradiotherapy: the added value of radiotherapy to molecularly targeted treatments
Seminars in Radiation Oncology (2006)
Defined the conceptual framework for molecularly targeted radiosensitization strategies.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Brian Marples
University of Rochester Medical Center
Silvia C. Formenti
Weill Cornell Medicine / NewYork-Presbyterian Hospital
Jeff Forman
Wayne State University / Karmanos Cancer Institute
Timothy N. Showalter
University of Virginia School of Medicine
关注 保罗·哈拉里 的研究动态
Follow Paul M. Harari's research updates
留下邮箱，当我们发布与 Paul M. Harari（University of Wisconsin School of Medicine and Public Health）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment